Sareum Holdings PLC Notification of PCA Shareholding (2912U)

TIDMSAR

RNS Number : 2912U

Sareum Holdings PLC

11 July 2018

 
 (AIM: SAR)   11 July 2018 
 

Sareum Holdings PLC

("Sareum" or "the Company")

Director/ PDMR Shareholding

Sareum announces that Susan Parker, wife of Dr Stephen Parker, Sareum's Chairman, purchased 609,756 of Ordinary Shares at a price of 0.82 pence per share yesterday. Following this transaction, Susan Parker now holds an interest of 1,284,028 Ordinary Shares in the company representing approximately 0.047% of the issued share capital of the Company. Dr. Parker and Susan Parker together now own a total of 1,745,977 Ordinary Shares, representing 0.064% of the Company's issued share capital.

For further information, please contact:

 
 Sareum Holdings plc 
 Tim Mitchell                            01223 497 700 
  WH Ireland Limited (Nominated 
   Adviser) 
 Chris Fielding / James Sinclair-Ford    020 7220 1666 
  Hybridan LLP (Broker) 
 Claire Noyce                            020 3764 2341 
  Citigate Dewe Rogerson (Media 
   enquiries) 
 Shabnam Bashir/ Mark Swallow/ 
  David Dible                            020 7282 9571 
 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
   1       Details of the person discharging managerial responsibilities/person closely associated 
   a)      Name                                                     Susan Parker 
        -------------------------------------------------------  ----------------------------------------------------- 
   2       Reason for the notification 
        -------------------------------------------------------------------------------------------------------------- 
   a)      Position/status                                          PCA as wife of Chairman, Dr Stephen Parker, Sareum 
                                                                    Holdings plc 
        -------------------------------------------------------  ----------------------------------------------------- 
   b)      Initial notification/ Amendment                          Initial Notification 
        -------------------------------------------------------  ----------------------------------------------------- 
   3       Details of the issuer, emission allowance market participant, auction platform, auctioneer 
            or auction monitor 
        -------------------------------------------------------------------------------------------------------------- 
   a)      Name                                                     Sareum Holdings plc 
        -------------------------------------------------------  ----------------------------------------------------- 
   b)      LEI                                                      213800PKERN2DY8FFM72 
        -------------------------------------------------------  ----------------------------------------------------- 
   4       Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
            each type of transaction; (iii) each date; and (iv) each place where transactions have been 
            conducted 
        -------------------------------------------------------------------------------------------------------------- 
   a)      Description of the financial instrument, type of         Ordinary Shares of 0.025p each 
           instrument 
 
           Identification code 
                                                                     GB00B02RFS12 
        -------------------------------------------------------  ----------------------------------------------------- 
   b)      Nature of the transaction                                Purchase of shares 
        -------------------------------------------------------  ----------------------------------------------------- 
   c)      Price(s) and volume(s)                                      Price(s)     Volume(s) 
                                                                        0.82p        609,756 shares 
                                                                                  ----------------- 
        -------------------------------------------------------  ----------------------------------------------------- 
   d)      Aggregated information 
     - Aggregated volume 
     - Price                                                         609,756 
                                                                      0.82p 
 --------------------------------------------------------------  ----------------------------------------------------- 
   e)      Date of the transaction                                   10th July 2018 
        -------------------------------------------------------  ----------------------------------------------------- 
   f)      Place of the transaction                                 London Stock Exchange, AIM 
        -------------------------------------------------------  ----------------------------------------------------- 
 

Notes for editors:

Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and undergoing Phase 2 clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in genetically defined patients both as a monotherapy and in combination with other oncology and immuno-oncology drugs.

Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.

The Company's drug discovery technology platform (SKIL(R) - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHUAOWRWNABARR

(END) Dow Jones Newswires

July 11, 2018 04:38 ET (08:38 GMT)